Asia-Pacific pen needles market is expected to reach USD 0.76 billion by 2023 from USD 0.4 billion in 2018, growing at a CAGR of 14.10% for the next five years 2018-2023. Pen needles are used to deliver the medication (such as insulin or other injectable medications) in combination with injection pens. A pen needle comprises of hollow needle attached to injection pen. Pen needles are available with varied needle lengths and are majorly utilized by diabetes patients.
Quickly rising diabetic population, growing number of awareness programs on diabetes conditions, and increasing adoption of pen devices for insulin delivery are driving the growth of pen needles market in Asia-Pacific region. However, increasing reuse of pen needles, limited acceptance of diabetic patients towards the pen needles, and higher cost of the pen needles as compared to conventional syringes & vials are restraining the growth of Asia-Pacific pen needles market.
Asia-Pacific pen needles market is segmented based on the therapy, type, needle length, and mode of purchase. On the based on therapy the market is further sub-segmented as insulin therapy, glucose like peptide-1 (GLP-1) therapy, and growth hormone therapy. The market, by type, is sub-segmented as safety needles and standard needles. The needle lengths include 4mm, 6mm, 8mm, 10mm, & 12mm. Based on mode of purchase the market is further sub-segmented as retail & non-retail purchase modes.
Based on therapy, insulin therapy is estimated to command the largest share of the Asia-Pacific pen needles market in 2018 and expected to grow at the highest CAGR during the forecast period 2018-2023. Based on type, standard pen needle segment is estimated to account for larger share of Asia-Pacific pen needles market in 2018, whereas safety pen needles segments is estimated to grow at a higher CAGR for the next five years (2018-2023).
Among the length of pen needles, 8mm is estimated to command for the largest share of the Asia-Pacific pen needles market in 2018 and 4mm is expected to grow at the highest CAGR during the forecast period. Based on the mode of purchase retail purchase mode is estimated to account for larger share of the Asia-Pacific pen needles market in 2018 and expected to grow at a higher CAGR for the next five years (2018-2023).
On the basis of geographical areas, Asia-Pacific pen needles market is segmented as Japan, China, and India. Japan is estimated to account for the largest share of the Asia-Pacific pen needles market in 2018, whereas India is estimated to grow at the highest CAGR during the forecast period 2018-2023.
Becton, Dickinson and Company (U.S.), Novo Nordisk A/S (Denmark), and Ypsomed Holding AG (Switzerland) are the major players accounting for major share of the Asia-Pacific pen needles market in 2018. Other players include UltiMed, Inc. (U.S.), Allison Medical, Inc. (U.S.), Owen Mumford, Ltd. (U.K.), B. Braun Melsungen (Germany), Artsana S.p.a. (Italy), HTL-STREFA S.A. (Poland), and Terumo Corporation (Japan), among others.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Therapy
5.1.1 Introduction
5.1.2 Insulin Therapy
5.1.3 GLP-1 Therapy Growth Hormone Therapy
5.1.4 Growth Hormone Therapy
5.2 Type
5.2.1 Introduction
5.2.2 Standard Needle
5.2.3 Safety Needle
5.3 Needle Length
5.3.1 Introduction
5.3.2 4mm
5.3.3 6mm
5.3.4 8mm
5.3.5 10mm
5.3.6 12mm
5.4 Mode of Purchase
5.4.1 Introduction
5.4.2 Retail
5.4.3 Non-Retail
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Becton, Dickinson and Company (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Novo Nordisk A/S (Denmark)
8.3 Ypsomed Holding AG (Switzerland)
8.4 UltiMed, Inc. (U.S.)
8.5 Allison Medical, Inc. (U.S.)
8.6 Owen Mumford, Ltd. (U.K.)
8.7 B. Braun Melsungen (Germany)
8.8 Artsana S.p.a. (Italy)
8.9 HTL-STREFA S.A. (Poland)
8.10 Terumo Corporation (Japan)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
